Intranasal drug developer Impel NeuroPharma has raised $67.5 million in a Series D financing round led by KKR and Norwest Venture Partners, the company said. Existing investors Vivo Capital, 5AM Ventures and venBio Partners also participated. According to Impel, the funds will be used to accelerate development of its pipeline of drugs based on its Precision Olfactory Delivery (POD) technology.
Impel CEO Jon Congleton said, “With three product candidates progressing through various stages of clinical development in 2018, it has been an exciting year for Impel, and this financing confirms the value that we are generating with our clinical programs.”
Clinical trials announced by Impel in 2018 include a Phase 1 study of INP105 intranasal olanzapine for the treatment of acute agitation in bipolar I and schizophrenia disorders, a Phase 2a trial of INP103 intranasal levodopa for the treatment of OFF episodes in Parkinson’s disease patients, and a Phase 3 trial of INP104 intranasal dihydroergotamine (DHE) for the treatment of migraine.
Read the Impel NeuroPharma press release.
